Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...
Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...
Effects of perioperative chemotherapy on prognosis in muscle invasive bladder cancer treated with radical cystectomy. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
Liao delivered a state-of-the-art lecture on Computer Vision in Endourology, highlighting how artificial intelligence (AI) ...
Bladder cancer affects over 52,000 men and women in the United States on an annual basis, and more than 12,000 people die each year from this disease. It is the fourth most common cancer in men in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results